

Atopic Dermatitis: Update Bulletin #2 [March 2018]

<https://marketpublishers.com/r/AE94DABF513EN.html>

Date: February 2018

Pages: 0

Price: US\$ 1,095.00 (Single User License)

ID: AE94DABF513EN

Abstracts

This edition presents key opinion leader (KOL) views on recent developments in the treatment of atopic dermatitis (AD). Topics covered include KOL views on; Pfizer's announcement of initiation of the global Phase III JADE development program for the Janus Kinase 1 (JAK1) inhibitor, PF 04965842, in patients as young as 12 with moderate to severe AD; AbbVie's presentation of new positive Phase IIb data concerning the JAK1-selective inhibitor, upadacitinib, indicating efficacy across all dosage strengths in adult patients with moderate to severe AD; and Dermira's initiation of a Phase IIb dose-ranging study evaluating the safety and efficacy of the anti-interleukin-13 (anti-IL-13) monoclonal antibody (mAb), lebrikizumab, following promising Phase II results in adult patients with moderate to severe AD.

Business Questions:

In December 2017, Pfizer announced initiation of the Phase III JADE global development program investigating the safety and efficacy of the Janus Kinase 1 (JAK1) inhibitor PF 04965842 in the treatment of moderate to severe atopic dermatitis (AD), but how do KOLs view this novel therapy, and what advantages does it offer over existing treatments?

How robust is Pfizer's Phase III trial design and how significant is the decision to include patients as young as 12 years of age?

How promising is the Phase IIb data for AbbVie's JAK1 inhibitor upadacitinib, presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego?

What concerns, if any, do KOLs have with regard to the use of JAK1 inhibitors for the treatment of moderate to severe AD?

Where will JAK1 inhibitors sit within the current treatment paradigm, given the recent approval of the monoclonal antibody (MAb) Dupixent (dupilumab; Sanofi/Regeneron) for the indication of AD?

Can the AD market accommodate multiple JAK inhibitors and how will prescribers differentiate between them?

How do KOLs perceive the anti-interleukin-13 (anti-IL-13) MAb lebrikizumab, following Dermira's publication of data from the Phase II proof-of-concept TREBLE study?

Do KOLs have any concerns regarding the potential of lebrikizumab for the treatment of AD, particularly given the decision to terminate further development of the product for the indication of asthma?

How successfully will lebrikizumab compete with Dupixent, the first MAb therapy to receive approval for the treatment of AD?

I would like to order

Product name: Atopic Dermatitis: Update Bulletin #2 [March 2018]

Product link: <https://marketpublishers.com/r/AE94DABF513EN.html>

Price: US\$ 1,095.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AE94DABF513EN.html>